VistaGen Therapeutics, Inc. (NASDAQ:VTGN) Stock Has Average Target Price of $0.95 According to Brokerages

Posted by Geri Gentry on Oct 13th, 2026

VistaGen Therapeutics, Inc. (NASDAQ:VTGN – Get Free Report) has earned an average recommendation of “Reduce” from the five brokerages that are presently covering the stock, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell recommendation and four have issued a hold recommendation on the company. The average 1-year target price among brokers that have issued a report on the stock in the last year is $0.95.

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of VistaGen Therapeutics in a research report on Monday, August 31st.

View Our Latest Report on VTGN

Institutional Investors Weigh In On VistaGen Therapeutics

Large investors have recently added to or reduced their stakes in the business. BlackRock Inc. purchased a new stake in shares of VistaGen Therapeutics in the second quarter valued at about $78,000. ADAR1 Capital Management LLC acquired a new stake in shares of VistaGen Therapeutics in the second quarter valued at approximately $79,000. Renaissance Technologies LLC grew its position in shares of VistaGen Therapeutics by 81.2% in the first quarter. Renaissance Technologies LLC now owns 291,300 shares of the company’s stock valued at $166,000 after purchasing an additional 130,509 shares during the last quarter. AdvisorShares Investments LLC increased its stake in shares of VistaGen Therapeutics by 10.8% during the 1st quarter. AdvisorShares Investments LLC now owns 277,110 shares of the company’s stock worth $158,000 after purchasing an additional 26,922 shares in the last quarter. Finally, Seven Fleet Capital Management LP purchased a new position in shares of VistaGen Therapeutics during the 4th quarter worth approximately $42,000. 78.39% of the stock is owned by institutional investors and hedge funds.

VistaGen Therapeutics Stock Down 4.7%

NASDAQ VTGN traded down $0.01 during mid-day trading on Tuesday, hitting $0.22. The stock had a trading volume of 186,549 shares, compared to its average volume of 5,010,192. VistaGen Therapeutics has a 52-week low of $0.20 and a 52-week high of $5.14. The company has a market cap of $9.59 million, a price-to-earnings ratio of -0.13 and a beta of 0.33. The company has a 50 day simple moving average of $0.26 and a 200 day simple moving average of $0.42.

VistaGen Therapeutics (NASDAQ:VTGN – Get Free Report) last posted its earnings results on Friday, August 14th. The company reported ($0.30) EPS for the quarter, topping analysts’ consensus estimates of ($0.36) by $0.06. The company had revenue of $1.48 million for the quarter, compared to the consensus estimate of $0.50 million. VistaGen Therapeutics had a negative return on equity of 152.59% and a negative net margin of 2,702.64%. As a group, equities analysts anticipate that VistaGen Therapeutics will post -1.45 earnings per share for the current fiscal year.

About VistaGen Therapeutics

(Get Free Report)

VistaGen Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing therapies for central nervous system disorders, with an emphasis on anxiety, depression and related conditions. The company is headquartered in South San Francisco, California, and conducts its development activities primarily in the United States.

VistaGen’s lead product candidate is fasedienol, also known as PH94B, an investigational neuroactive nasal spray being developed for the treatment of social anxiety disorder and other anxiety-related conditions.